Kura Oncology and Kyowa Kirin Announce Combination Data for Ziftomenib in Oral Presentation at ...

Kura Oncology and Kyowa Kirin Announce Combination Data for Ziftomenib in Oral Presentation at ...

– Ziftomenib combined with 7+3 in 1L NPM1 -m or KMT2A -r AML patients selected for oral presentation on Thursday, June 12th –

Kura Oncology and Kyowa Kirin Announce Combination Data for Ziftomenib in Oral Presentation at the 2025 European Hematology Association (EHA) Congress - Kura Oncology (NASDAQ:KURA)

– Ziftomenib combined with 7+3 in 1L NPM1-m or KMT2A-r AML patients selected for oral presentation on Thursday, June 12th – – Updated dataset to be presented in oral presentation at EHA2025 Congress – SAN DIEGO and TOKYO, May 14, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA, "Kura")) and Kyowa Kirin Co., Ltd. (TSE: 4151, "Kyowa Kirin") today announced that an abstract highlighting clinical data from the KOMET-007 combination trial o…